The Suntrust Banks Inc. Purchases 166 Shares of West Pharmaceutical Services Inc. (WST)

The Suntrust Banks Inc. Purchases 166 Shares of West Pharmaceutical Services Inc. (WST)

Suntrust Banks Inc. boosted its stake in West Pharmaceutical Services Inc. (NYSE:WST) by 1.8% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 9,149 shares of the company’s stock after buying an additional 166 shares during the period. Suntrust Banks Inc.’s holdings in West Pharmaceutical Services were worth $679,000 at the end of the most recent reporting period.

A number of other large investors have also recently modified their holdings of the company. IBM Retirement Fund purchased a new stake in shares of West Pharmaceutical Services during the second quarter valued at $550,000. Checchi Capital Advisers LLC boosted its stake in West Pharmaceutical Services by 41,428.6% in the second quarter. Checchi Capital Advisers LLC now owns 2,907 shares of the company’s stock worth $221,000 after buying an additional 2,900 shares in the last quarter. New York State Teachers Retirement System boosted its stake in West Pharmaceutical Services by 0.5% in the second quarter. New York State Teachers Retirement System now owns 131,270 shares of the company’s stock worth $9,961,000 after buying an additional 600 shares in the last quarter. Retirement Systems of Alabama boosted its stake in West Pharmaceutical Services by 1.1% in the second quarter. Retirement Systems of Alabama now owns 94,267 shares of the company’s stock worth $7,153,000 after buying an additional 996 shares in the last quarter. Finally, First Midwest Bank Trust Division boosted its stake in West Pharmaceutical Services by 47.0% in the second quarter. First Midwest Bank Trust Division now owns 10,645 shares of the company’s stock worth $808,000 after buying an additional 3,403 shares in the last quarter. 89.67% of the stock is currently owned by institutional investors.

Shares of West Pharmaceutical Services Inc. (NYSE:WST) traded down 0.75% on Thursday, hitting $83.72. The stock had a trading volume of 187,368 shares. West Pharmaceutical Services Inc. has a 12 month low of $53.88 and a 12 month high of $88.30. The company has a market cap of $6.13 billion, a P/E ratio of 45.28 and a beta of 0.95. The company’s 50 day moving average price is $84.48 and its 200-day moving average price is $79.59.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings results on Thursday, October 27th. The company reported $0.53 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.53. West Pharmaceutical Services had a return on equity of 14.54% and a net margin of 9.27%. The firm earned $376.70 million during the quarter, compared to analyst estimates of $371.76 million. During the same period last year, the company earned $0.44 EPS. West Pharmaceutical Services’s quarterly revenue was up 9.3% compared to the same quarter last year. On average, analysts expect that West Pharmaceutical Services Inc. will post $2.21 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, February 1st. Investors of record on Wednesday, January 18th will be paid a dividend of $0.13 per share. This represents a $0.52 dividend on an annualized basis and a dividend yield of 0.62%. The ex-dividend date of this dividend is Friday, January 13th. West Pharmaceutical Services’s dividend payout ratio is currently 28.11%.

A number of research firms have recently commented on WST. Zacks Investment Research raised West Pharmaceutical Services from a “sell” rating to a “hold” rating in a research note on Wednesday, December 7th. Janney Montgomery Scott reissued a “buy” rating on shares of West Pharmaceutical Services in a research note on Friday, December 23rd. Finally, Wells Fargo & Co. raised West Pharmaceutical Services from a “market perform” rating to an “outperform” rating in a research note on Friday, October 28th.

In other news, Director Patrick J. Zenner bought 332 shares of the firm’s stock in a transaction on Thursday, December 8th. The stock was acquired at an average cost of $84.53 per share, with a total value of $28,063.96. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Paula A. Johnson sold 2,466 shares of West Pharmaceutical Services stock in a transaction on Monday, October 31st. The shares were sold at an average price of $75.87, for a total value of $187,095.42. The disclosure for this sale can be found here. 5.13% of the stock is currently owned by company insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc (West) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries. The Company’s segments include Pharmaceutical Packaging Systems segment (Packaging Systems) and the Pharmaceutical Delivery Systems segment (Delivery Systems).

Want to see what other hedge funds are holding WST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for West Pharmaceutical Services Inc. (NYSE:WST).

Related posts

Leave a Comment